RCUS
Arcus Biosciences, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Neutral
-2/100
Last price
24.28
▼ 0.46 (1.86%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
24.96
Prev close
24.74
Day high
24.84
Day low
23.96
Volume
824.85K
Market cap
$3.05B
P/E (TTM)
—
52W range
14.18 – 31.74
Day trading desk
Gap from prior close
+0.89%
Prior close 24.74
VWAP
24.33
-0.19% from price
Relative volume
1.10×
Normal
Session range
5.32%
23.70 – 24.96
Position in range
46%
Mid range
ATR (14D)
1.21
4.97% of price
Prior day high
24.95
PDH
Prior day low
24.10
PDL
Bid / ask spread
—
Quote not published
Session volume
1.46M
Avg 1.33M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.34%
-7.3%
1M
-18.14%
-19.3%
3M
-19.76%
-24.3%
6M
+10.01%
-8.2%
YTD
+1.89%
-12.4%
1Y
+81.87%
+65.5%
3Y
+35.26%
-47.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on RCUS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-31.29K
Net selling
Buy transactions
10
81.87K shares
Sell transactions
5
113.15K shares
Net transactions
+15
Buys less sells
Sell : buy shares
1.4 : 1
Mixed
Insider-held shares
36.67M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 21, 26 | AZOY ALEXANDER Officer |
SELL | 2.83K | $84.81K | Direct |
| Aug 21, 26 | AZOY ALEXANDER Officer |
CONVERSION | 2.83K | $43.65K | Direct |
| Jul 10, 26 | JAEN JUAN CARLOS President |
SELL | 68.57K | $2.03M | Indirect |
| Jun 24, 26 | JAEN JUAN CARLOS President |
SELL | 31.43K | $877.50K | Indirect |
| Jun 11, 26 | MACHADO PATRICK Director |
STOCK | 5.70K | $0 | Direct |
| Jun 11, 26 | LACEY DAVID L Director |
STOCK | 5.70K | $0 | Direct |
| Jun 11, 26 | LAMBERT NICOLE Director |
STOCK | 5.70K | $0 | Direct |
| Jun 11, 26 | RIBAS ANTONI Director |
STOCK | 5.70K | $0 | Direct |
| Jun 11, 26 | TANG CAROLYN C. General Counsel |
CONVERSION | 34.09K | $87.75K | Direct |
| Jun 11, 26 | PERLMAN ANDREW J Director |
STOCK | 5.70K | $0 | Direct |
| Jun 11, 26 | FALBERG KATHRYN E. Director |
STOCK | 5.70K | $0 | Direct |
| Jun 11, 26 | KANEKO YASUNORI Director |
STOCK | 5.70K | $0 | Direct |
| Jun 1, 26 | AZOY ALEXANDER Officer |
SELL | 2.56K | $66.02K | Direct |
| May 11, 26 | GOELTZ ROBERT C. II Chief Financial Officer |
SELL | 7.76K | $198.97K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
FALBERG KATHRYN E. |
Director | 176.41K | Stock Award(Grant) |
GILEAD SCIENCES INC |
Beneficial Owner of more than 10% of a Class of Security | 31.42M | Purchase |
GOELTZ ROBERT C. II |
Chief Financial Officer | 84.16K | Sale |
JAEN JUAN CARLOS |
President | — | Sale |
JARRETT A JENNIFER |
Chief Operating Officer | 224.02K | Stock Award(Grant) |
KANEKO YASUNORI |
Director | 957.96K | Stock Award(Grant) |
LACEY DAVID L |
Director | 76.65K | Stock Award(Grant) |
MARKUS RICHARD M.D., PH.D. |
Officer | 89.65K | Stock Award(Grant) |
ROSEN TERRY JAY |
Chief Executive Officer | 2.24M | Stock Award(Grant) |
TANG CAROLYN C. |
General Counsel | 184.61K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$3.05B
Enterprise value$2.63B
Revenue (TTM)$117.00M
Gross profit$-380.00M
EBITDA$-476.00M
Net income$-460.00M
EPS (TTM)$-3.84
Free cash flow$-270.62M
Total cash$702.00M
Total debt$238.00M
Book value / share$3.65
Shares outstanding125.77M
Float90.53M
Short % of float17.71%
Dividend yield0.00%
Beta (5Y)0.94
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.43
PEG ratio—
Price / sales—
Price / book6.64
EV / revenue22.46
EV / EBITDA-5.52
Gross margin0.00%
Operating margin-234.15%
Profit margin0.00%
Return on equity-90.82%
Return on assets-30.39%
Debt / equity51.29
Current ratio3.82
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $247.00M | $258.00M | $117.00M | $112.00M | -4.3% |
| Operating revenue | $247.00M | $258.00M | $117.00M | $112.00M | -4.3% |
| Research & development | $523.00M | $448.00M | $340.00M | $288.00M | +16.7% |
| Selling, general & admin | $110.00M | $120.00M | $117.00M | $104.00M | -8.3% |
| Total operating expense | $633.00M | $568.00M | $457.00M | $392.00M | +11.4% |
| Operating income | -$386.00M | -$310.00M | -$340.00M | -$280.00M | -24.5% |
| Net interest income | $33.00M | $48.00M | $39.00M | $14.00M | -31.3% |
| Pre-tax income | -$353.00M | -$282.00M | -$301.00M | -$266.00M | -25.2% |
| Tax provision | $0 | $1.00M | $6.00M | $1.00M | -100.0% |
| Net income | -$353.00M | -$283.00M | -$307.00M | -$267.00M | -24.7% |
| Net income to common | -$353.00M | -$283.00M | -$307.00M | -$267.00M | -24.7% |
| Basic EPS | -3.29 | -3.14 | -4.15 | -3.71 | -4.8% |
| Diluted EPS | -3.29 | -3.14 | -4.15 | -3.71 | -4.8% |
| EBIT | -$345.00M | -$278.00M | -$299.00M | -$264.00M | -24.1% |
| EBITDA | -$335.00M | -$268.00M | -$291.00M | -$258.00M | -25.0% |
| Basic shares | 107.40M | 90.10M | 74.00M | 72.00M | +19.2% |
| Diluted shares | 107.40M | 90.10M | 74.00M | 72.00M | +19.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $222.00M | $150.00M | $127.00M | $206.00M | +48.0% |
| Cash & short-term investments | $981.00M | $978.00M | $759.00M | $1.01B | +0.3% |
| Accounts receivable | $11.00M | $20.00M | $38.00M | $39.00M | -45.0% |
| Total current assets | $1.01B | $1.02B | $831.00M | $1.07B | -0.9% |
| Property, plant & equipment | $40.00M | $47.00M | $51.00M | $35.00M | -14.9% |
| Total assets | $1.14B | $1.15B | $1.09B | $1.34B | -1.0% |
| Total current liabilities | $231.00M | $226.00M | $184.00M | $193.00M | +2.2% |
| Long-term debt | $99.00M | $48.00M | — | — | +106.3% |
| Total debt | $112.00M | $60.00M | $11.00M | $3.00M | +86.7% |
| Total liabilities | $508.00M | $665.00M | $633.00M | $688.00M | -23.6% |
| Retained earnings | -$1.49B | -$1.13B | -$849.00M | -$542.00M | -31.2% |
| Shareholder equity | $631.00M | $485.00M | $462.00M | $657.00M | +30.1% |
| Working capital | $776.00M | $790.00M | $647.00M | $874.00M | -1.8% |
| Net tangible assets | $631.00M | $485.00M | $462.00M | $657.00M | +30.1% |
| Shares issued | 125.30M | 92.20M | 75.50M | 72.90M | +35.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$353.00M | -$283.00M | -$307.00M | -$267.00M | — | -24.7% |
| Depreciation & amortisation | $10.00M | $10.00M | $8.00M | $6.00M | — | 0.0% |
| Stock-based compensation | $60.00M | $76.00M | $73.00M | $65.00M | — | -21.1% |
| Change in working capital | -$194.00M | $22.00M | -$71.00M | $623.00M | — | -981.8% |
| Operating cash flow | -$482.00M | -$170.00M | -$306.00M | $438.00M | — | -183.5% |
| Capital expenditure | -$2.00M | -$6.00M | -$24.00M | -$6.00M | — | +66.7% |
| Investing cash flow | $66.00M | -$84.00M | $194.00M | -$413.00M | — | +178.6% |
| Share buybacks | — | — | — | — | -$6.00K | — |
| Financing cash flow | $488.00M | $277.00M | $33.00M | $33.00M | — | +76.2% |
| Free cash flow | -$484.00M | -$176.00M | -$330.00M | $432.00M | — | -175.0% |
| End cash position | $225.00M | $153.00M | $130.00M | $209.00M | — | +47.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $41.00M | $17.00M | $33.00M | $26.00M | $160.00M | +141.2% |
| Operating revenue | $41.00M | $17.00M | $33.00M | $26.00M | $160.00M | +141.2% |
| Research & development | $113.00M | $122.00M | $121.00M | $141.00M | $139.00M | -7.4% |
| Selling, general & admin | $24.00M | $29.00M | $26.00M | $27.00M | $29.00M | -17.2% |
| Total operating expense | $137.00M | $151.00M | $147.00M | $168.00M | $168.00M | -9.3% |
| Operating income | -$96.00M | -$134.00M | -$114.00M | -$142.00M | -$8.00M | +28.4% |
| Net interest income | $5.00M | $6.00M | $8.00M | $7.00M | $8.00M | -16.7% |
| Pre-tax income | -$91.00M | -$128.00M | -$106.00M | -$135.00M | $0 | +28.9% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$91.00M | -$128.00M | -$106.00M | -$135.00M | $0 | +28.9% |
| Net income to common | -$91.00M | -$128.00M | -$106.00M | -$135.00M | $0 | +28.9% |
| Basic EPS | -0.72 | -1.02 | -0.89 | -1.27 | 0.00 | +29.4% |
| Diluted EPS | -0.72 | -1.02 | -0.89 | -1.27 | 0.00 | +29.4% |
| EBIT | -$88.00M | -$125.00M | -$104.00M | -$132.00M | $2.00M | +29.6% |
| EBITDA | -$85.00M | -$123.00M | -$101.00M | -$130.00M | $4.00M | +30.9% |
| Basic shares | 126.10M | 125.40M | 118.50M | 106.50M | 106.10M | +0.6% |
| Diluted shares | 126.10M | 125.40M | 118.50M | 106.50M | 106.50M | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $150.00M | $201.00M | $222.00M | $238.00M | $248.00M | -25.4% |
| Cash & short-term investments | $702.00M | $822.00M | $981.00M | $831.00M | $911.00M | -14.6% |
| Accounts receivable | $36.00M | $3.00M | $11.00M | $11.00M | $15.00M | +1,100.0% |
| Total current assets | $756.00M | $844.00M | $1.01B | $857.00M | $946.00M | -10.4% |
| Property, plant & equipment | $36.00M | $38.00M | $40.00M | $42.00M | $44.00M | -5.3% |
| Total assets | $924.00M | $997.00M | $1.14B | $974.00M | $1.07B | -7.3% |
| Total current liabilities | $198.00M | $209.00M | $231.00M | $235.00M | $210.00M | -5.3% |
| Long-term debt | $101.00M | $100.00M | $99.00M | $98.00M | $97.00M | +1.0% |
| Total debt | $114.00M | $113.00M | $112.00M | $111.00M | $109.00M | +0.9% |
| Total liabilities | $460.00M | $473.00M | $508.00M | $538.00M | $526.00M | -2.7% |
| Retained earnings | -$1.70B | -$1.61B | -$1.49B | -$1.38B | -$1.24B | -5.6% |
| Shareholder equity | $464.00M | $524.00M | $631.00M | $436.00M | $549.00M | -11.5% |
| Working capital | $558.00M | $635.00M | $776.00M | $622.00M | $736.00M | -12.1% |
| Net tangible assets | $464.00M | $524.00M | $631.00M | $436.00M | $549.00M | -11.5% |
| Shares issued | 127.00M | 125.50M | 125.30M | 107.10M | 106.40M | +1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$91.00M | -$128.00M | -$106.00M | -$135.00M | $0 | — | +28.9% |
| Depreciation & amortisation | $3.00M | $2.00M | $3.00M | $2.00M | $2.00M | — | +50.0% |
| Stock-based compensation | $15.00M | $19.00M | $15.00M | $14.00M | $15.00M | — | -21.1% |
| Change in working capital | -$47.00M | -$31.00M | -$30.00M | $21.00M | -$148.00M | — | -51.6% |
| Operating cash flow | -$119.00M | -$138.00M | -$120.00M | -$97.00M | -$133.00M | — | +13.8% |
| Capital expenditure | — | — | -$1.00M | — | — | -$1.00M | — |
| Investing cash flow | $52.00M | $114.00M | -$182.00M | $79.00M | $137.00M | — | -54.4% |
| Financing cash flow | $16.00M | $3.00M | $286.00M | $8.00M | $52.00M | — | +433.3% |
| Free cash flow | -$119.00M | -$138.00M | -$121.00M | -$97.00M | -$133.00M | — | +13.8% |
| End cash position | $153.00M | $204.00M | $225.00M | $241.00M | $251.00M | — | -25.0% |
Options analytics
Put / call volume
0.09
Call-heavy session
Put / call open interest
0.44
Positioning, not flow
Max pain
5.00
-79.4% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
+6.2%
Puts bid over calls
Call volume
2.42K
Contracts, this expiry
Put volume
211
Contracts, this expiry
Heaviest call OI
22.50
9 contracts
Heaviest put OI
5.00
4 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.81 | -0.72 | +11.6% |
| Mar 2026 | -0.83 | -1.02 | -23.3% |
| Dec 2025 | -1.08 | -0.89 | +17.2% |
| Sep 2025 | -1.29 | -1.27 | +1.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.86 | 7 | $12.37M | -52.4% |
| Next quarter | -0.82 | 7 | $8.37M | -74.6% |
| Current year | -3.48 | 7 | $78.61M | -68.2% |
| Next year | -3.27 | 7 | $50.68M | -35.5% |
Analyst targets & ownership
Mean target$39.91
High target$47.00
Low target$23.00
Implied upside64.37%
Analyst count11
ConsensusSTRONG BUY
Strong buy / Buy0 / 11
Hold2
Sell / Strong sell0 / 0
Held by insiders28.80%
Held by institutions74.92%
Institutions holding329
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
25.16
-3.50% from price
SMA 20
25.37
-4.31% from price
SMA 50
27.65
-12.19% from price
SMA 100
27.09
-10.36% from price
SMA 200
24.80
-2.08% from price
EMA 12
25.24
-3.79% from price
EMA 26
26.14
-7.10% from price
EMA 50
26.84
-9.53% from price
RSI (14)
37.2
Neutral
MACD (12,26,9)
-0.90
Hist -0.02
ATR (14)
1.21
4.97% of price
Realised vol 30D
46.6%
Annualised
Bollinger upper
27.43
20, 2σ
Bollinger lower
23.32
20, 2σ
50 / 200 cross
Golden
27.65 vs 24.80
Trend bias
Below 200
-2.08%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.77
More volatile than market
Correlation to SPY
0.37
Loosely linked
Realised vol 30D
46.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-27.8%
Peak to trough
Max drawdown 5Y
-85.8%
Peak to trough
ATR 14
1.21
4.97% of price
Beta (reported)
0.94
5Y monthly, from filing
Short interest
Shares short
13.81M
Prior 13.85M
Change vs prior
-0.3%
Shorts covering
% of float
17.71%
Elevated
% of shares out
10.85%
Against total outstanding
Days to cover
9.4
Crowded exit
Float
90.53M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 16, 26 | TD Cowen | INITIATED | — | Buy |
| Sep 8, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 6, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Aug 6, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jul 20, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 4, 26 | LifeSci Capital | INITIATED | — | Outperform |
| May 11, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| May 7, 26 | Goldman Sachs | MAINTAINED | Buy | Buy |
| Apr 2, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Mar 5, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Mar 2, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-06-12
Corporate Changes & Voting Matters
8-K · 2026-05-05
Proxy Statements
DEF 14A · 2026-04-21
Corporate Changes & Voting Matters
8-K · 2026-04-20
Corporate Changes & Voting Matters
8-K · 2026-03-23
Offering Registrations
S-3ASR · 2026-02-25
Corporate Changes & Voting Matters
8-K · 2025-12-18
Headlines
Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage?
Simply Wall St. · 7h ago
How Investors Are Reacting To Arcus Biosciences (RCUS) Expansive New Casdatifan ARC-20 Kidney Cancer Data
Simply Wall St. · 2d ago
Arcus Biosciences Announces New Employment Inducement Grants
Business Wire · 12d ago
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Business Wire · 15d ago
TD Cowen Initiates Arcus Biosciences at Buy
MT Newswires · 21d ago
Arcus Biosciences Announces New Employment Inducement Grants
Business Wire · 27d ago
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
Business Wire · 41d ago
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?
Insider Monkey · 54d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.